Get the Stockscreener App
0.3544
1.50%
-0.0054
Pre-market:
.35
-0.0044
-1.24%
Profusa Inc stock is traded at $0.3544, with a volume of 182.76K.
It is down -1.50% in the last 24 hours and down -34.54% over the past month.
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.
See More
Previous Close:
$0.3598
Open:
$0.36
24h Volume:
182.76K
Relative Volume:
0.04
Market Cap:
$1.65M
Revenue:
$75,000
Net Income/Loss:
$-42.41M
P/E Ratio:
-0.00197
EPS:
-179.8206
Net Cash Flow:
$-18.47M
1W Performance:
-5.79%
1M Performance:
-34.54%
6M Performance:
-97.21%
1Y Performance:
+0.00%
1-Day Range:
$0.345
$0.365
1-Week Range:
$0.3431
$0.39
52-Week Range:
$0.3431
$166.50
Profusa Inc Stock (PFSA) Company Profile
Name
Profusa Inc
Sector
Industry
Phone
212-494-9022
Address
207 WEST 25TH ST, 9TH FLOOR, NEW YORK
Compare PFSA vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFSA
Profusa Inc
|
0.3544 | 1.68M | 75,000 | -42.41M | -18.47M | -179.82 |
ABT
Abbott Laboratories
|
85.60 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.09 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
73.81 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
48.31 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.47 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Profusa Inc Stock (PFSA) Latest News
Profusa Shares Below 40 Cents as Nasdaq Deadline Nears - Bez Kabli
PFSA Stock Chart | PROFUSA INC (NASDAQ:PFSA) - ChartMill
PFSA | Profusa, Inc. Common Stock Executive Compensation - Quiver Quantitative
[ARS] Profusa, Inc. SEC Filing - Stock Titan
Profusa (NASDAQ: PFSA) eyes major reverse split, $30M PanOmics stock acquisition and note conversion - Stock Titan
Profusa Amends $30 Million Asset Purchase of PanOmics Assay, Drops 12% Management Equity Grant - TradingView
[8-K] Profusa, Inc. Reports Material Event - Stock Titan
PFSA Should I Buy - Intellectia AI
Profusa, Inc. Submits Advance Notice for Equity Line Share Purchase with Ascent Partners Fund LLC – SEC Filing 8-K May 18, 2026 - Minichart
Profusa submits equity purchase notice to Ascent Partners under credit agreement - Investing.com Nigeria
Profusa (NASDAQ: PFSA) registers 179.3M resale shares; Ascent equity line terms detailed - Stock Titan
Profusa Taps Equity Line for Near-Term Liquidity - TipRanks
Profusa submits advance notice to Ascent for up to 9.99% equity purchase with true-up mechanism - TradingView
Profusa (NASDAQ: PFSA) details May equity line share purchase terms - Stock Titan
Number of shareholders of Profusa, Inc. – NASDAQ:PFSA - TradingView
Profusa Transfers Nasdaq Listing Amid Ongoing Compliance Uncertainty - The Globe and Mail
PFSA Financials: Income Statement, Balance Sheet & Cash Flow | Profusa Inc - Stock Titan
Profusa, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Profusa (NASDAQ: PFSA) Q1 2026 loss deepens amid going concern and Nasdaq listing pressure - Stock Titan
Profusa, Inc. Announces Transfer to Nasdaq Capital Market to Ensure Continued Listing Compliance - Minichart
Profusa to Transfer Listing to The Nasdaq Capital Market Effective May 15, 2026 - TradingView
Profusa (Nasdaq: PFSA) shifts stock listing to Nasdaq Capital Market tier - Stock Titan
Profusa moves to Nasdaq Capital Market amid compliance efforts By Investing.com - Investing.com Australia
Profusa moves to Nasdaq Capital Market amid compliance efforts - Investing.com
Profusa Announces Listing Transfer to The Nasdaq Capital Market - The Manila Times
Profusa announces listing transfer to the Nasdaq Capital Market - marketscreener.com
Digital health company Profusa shifts Nasdaq tier to meet listing rules - Stock Titan
Profusa granted transfer to Nasdaq Capital Market, faces July compliance deadline - MSN
Profusa announces initial $1 million bitcoin investment to initiate its digital asset treasury strategy - MSN
Profusa (NASDAQ: PFSA) seeks vote on reverse split, $30M Bio Insights deal - Stock Titan
Number of shareholders of PROFUSA, INC. – OTC:NVACW - TradingView
NVACW | PROFUSA INC WTS Insider Trading - Quiver Quantitative
Profusa Granted Conditional Nasdaq Listing Extension and Transfer - TipRanks
Profusa Receives Favorable Nasdaq Listing Determination - The Manila Times
Profusa, Inc. Granted Transfer to Nasdaq Capital Market Amid Compliance Efforts - Quiver Quantitative
Conditional Nasdaq listing relief for Profusa (NASDAQ: PFSA) - Stock Titan
Profusa keeps Nasdaq listing if it meets July 6 price and equity rules - Stock Titan
Profusa Secures New Convertible Note and Warrant Financing - TipRanks
Profusa (PFSA) insider-linked LLC converts $1.87M note into 5.34M shares - Stock Titan
Profusa (PFSA) CFO-linked LLC converts $1,869,796 note into 5.34M shares - Stock Titan
Profusa initiates strategic review, focuses on European approval By Investing.com - Investing.com Australia
Profusa initiates strategic review, focuses on European approval - Investing.com
Profusa Inc Profusa initiates board-led process to evaluate strategic alternatives and maximize shareholder value - marketscreener.com
Profusa Inc Profusa Initiates Board-Led Process To Evaluate Strategic Alternatives And Maximize Shareholder Value - TradingView
Profusa Inc Stock (PFSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
1.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):